Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about Tiziana Life Sciences
Recent news which mentions Tiziana Life Sciences
Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab
November 30, 2023
Tickers
TLSA
Tags
General
News
Biotech
From
Benzinga
Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June
October 12, 2023
Tickers
TLSA
Tags
General
Partner Content
News
From
Benzinga
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
October 04, 2023
Tickers
RHHBY
SNY
TLSA
Tags
Penny Stocks
Benzinga
Market News
From
Benzinga
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients
September 27, 2023
Tickers
TLSA
Tags
Biotech
Tiziana Life Sciences
News
From
Benzinga
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light
September 12, 2023
Tickers
TLSA
Tags
Biotech
Tiziana Life Sciences
General
From
Benzinga
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision
August 16, 2023
Tickers
TLSA
Tags
General
Biotech
Tiziana Life Sciences
From
Benzinga
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
August 08, 2023
Tickers
BAYRY
SNY
TLSA
Tags
Penny Stocks
Benzinga
TLSA
From
Benzinga
Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon
August 03, 2023
Tickers
SNY
TLSA
Tags
TLSA
Market News
Benzinga
From
Benzinga
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
July 26, 2023
Tags
Biotech
Tiziana Life Sciences
Partner Content
From
Benzinga
Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment
July 17, 2023
Tickers
BAYRY
SNY
TSLA
Tags
BAYRY
Market News
Benzinga
From
Benzinga
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA)
July 10, 2023
Tickers
SNY
TLSA
Tags
General
Tiziana Life Sciences
Biotech
From
Benzinga
Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company?
June 15, 2023
Tickers
PRVB
SNY
TLSA
Tags
Market News
TLSA
Benzinga
From
Benzinga
Tiziana's Foralumab Shown To Reduce Microglial Activation In MS Patients; Phase 2a Trial To Begin In Q3 2023
June 06, 2023
Tickers
TLSA
Tags
Penny Stocks
Benzinga
Market News
From
Benzinga
Tiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a Trial
April 21, 2023
Tickers
TLSA
Tags
News
Biotech
Tiziana Life Sciences
From
Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tickers
EWTX
IPHA
PRVB
SGEN
Tags
SNY
Partner Content
PRVB
From
Benzinga
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise
April 12, 2023
Tickers
PRVB
SNY
TLSA
Tags
Benzinga
Penny Stocks
TLSA
From
Benzinga
Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
March 29, 2023
Tickers
TLSA
Tags
TLSA
Market News
Benzinga
From
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.